Skip to main content

Advertisement

SpringerLink
Log in

Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

There are a limited number of studies comparing outcomes of busulfan (BU)-based myeloablative hematopoietic stem cell transplantation using unmanipulated haploidentical donors (HIDs), HLA-matched unrelated donors (MUDs), and HLA-matched sibling related donors (MSDs) in acute myeloid leukemia (AML) patients with complete remission (CR) status. With this background, we compared outcomes among 377 cases of CR following consecutive HID-HSCT for AML (CR) to 86 MUD and 92 MSD-HSCT cases. All patients received BU-based myeloablative conditioning and an unmanipulated graft within the same period. The median patient age was 23 years (range 1.1 to 65 years), and 230 patients (41.4%) were under age18. Among the 555 patients, 432 (77.8%) were of intermediate cytogenetic risk and 123 (22.2%) were of adverse risk. A total of 113 patients (20.5%) had FLT3-ITD+ AML, 425 patients (76.6%) were in first complete remission (CR1) post-transplant, and 130 (23.4%) patients were in second CR (CR2). GVHD prophylaxis included mycophenolate mofetil (MMF), cyclosporine-A (CSA) with short-term methotrexate (MTX) for HID, and MUD-HSCT. MMF is not used for MSD-HSCT. The median survival follow-up time was 42 months (range 18–91 months). The 3-year leukemia-free survival (LFS) among the HID, MUD, and MSD cohorts was 73.8% ± 4.8%, 66.4% ± 8.5%, 74.5% ± 2.4%, respectively (P = 0.637). Three-year overall survival (OS) was 74.9% ± 2.4%, 81.8% ± 4.3%, and 77.5% ± 4.5% among the HID, MUD, and MSD cohorts, respectively (P = 0.322). There were no difference among the relapse rate among the HID, MUD, and MSD donor cohorts (14.3% ± 4.0% vs 20.3% ± 6.4% vs 14.5% ± 2.2, respectively; P = 0.851) or the non-relapse mortality (NRM) (12.3% ± 3.5% vs 9.5% ± 3.2% vs 14.0% ± 1.8%, respectively; P = 0.441). Multivariate analyses showed that MRD-positive pre-HSCT was the only risk factor associated with a lower OS and LFS and higher risk of relapse among all 555 patients. Compared with the use of a MUD or MSD, an HID for HSCT had similar outcomes among AML patients with CR states who underwent an allo-HSCT with BU-based myeloablative conditioning. MFC-MRD-positive pre-HSCT was an independent negative factor impact on outcomes for AML patients in CR. We conclude that for AML patients who do not have a MSD or if an urgent transplant is required, HSCT from an HID is a valid option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. Version 3. 2020. (Guidelines)

  2. Versluis J, Labopin M, Ruggeri A, Socie G et al (2017) Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv 1(7):477–485

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Giebel S, Boumendil A, Labopin M (2019) Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Ann Hematol 98:2389–2398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Rashidi A, Slade M, DiPersio JF, Westervelt P et al (2016) Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. Bone Marrow Transplant 51:1561–1564

    Article  CAS  PubMed  Google Scholar 

  5. Bashey A, Xu Z, Jackson K et al (2016) Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant 22:125e133

    Article  Google Scholar 

  6. Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127(20):2391–2405

    Article  CAS  PubMed  Google Scholar 

  7. Yu W, Chang Y-J, Xu L-P et al (2014) Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 124(6):843–850

    Article  Google Scholar 

  8. Slovak ML, Kopecky KJ, Peter A. Cassileth, et al. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 96(13):4075–4083

    Article  CAS  PubMed  Google Scholar 

  9. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an International Expert Panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 106(8):2912–2919

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Stefan O Ciurea , Kai Cao, Marcelo Fernandez-Vina, Piyanuch Kongtim, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant2018;53(5):521-534.

  12. Lu D-P, Dong L, Wu T, Huang X-J et al (2006) Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 107(8):3065–3073

    Article  CAS  PubMed  Google Scholar 

  13. Harris AC, Young R, Devine S et al (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 22:4e10

    Article  Google Scholar 

  14. Jagasia MH, Hildegard T, Greinix MA et al (2015) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 21(3):389–401

    Article  PubMed  Google Scholar 

  15. Di Stasi A, Milton DR, Poon LM et al (2014) Similar transplant outcomes for AML/MDS patients with haploidentical versus 10/10 HLA matched unrelated and related donors. Biol Blood Marrow Transplant 20(12):1975–1981

    Article  PubMed  PubMed Central  Google Scholar 

  16. Yu W, Liu Q-F, Xu L-P, Liu K-Y et al (2015) Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 125(25):3956–3962

    Article  Google Scholar 

  17. Salvatore D, Labopin M, Ruggeri A et al (2018) Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 103(8):1317–1328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ringdén O, Labopin M, Ciceri F, Velardi A et al (2016) Is there a stronger graft-versus-leukemia effect using HLA haploidentical donors than with HLA-identical siblings? Leukemia. 30(2):447–455

    Article  PubMed  Google Scholar 

  19. Chang Y-J, Yu W, Liu Y-R, Xu L-P et al (2017) Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol 10(1):134

    Article  PubMed  PubMed Central  Google Scholar 

  20. Yu W, Liu D-H, Xu L-P, Liu K-Y et al (2011 Jun) Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 17(6):821–830

    Article  Google Scholar 

  21. Getta BM, Devlin SM, Levine RL et al (2017) Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation. Biol Blood Marrow Transplant 23:1064–1071

    Article  CAS  PubMed  Google Scholar 

  22. Feng S, Zhou L, Zhang X, Tang B, Zhu X et al (2019) Impact of ELN risk stratification, induction chemotherapy regimens and hematopoietic stem cell transplantation on outcomes in hyperleukocytic acute myeloid leukemia with initial white blood cell count more than 100 × 109/L. Cancer Manag Res 11:9495–9503

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Schmaelter A-K, Labopin M, Socié G, Itälä-Remes M et al (2020) Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J 10(3):26

    Article  PubMed  PubMed Central  Google Scholar 

  24. Ning Xie MD, Jian Zhou PD, Yanli Zhang MD et al (2019 May) Extramedullary relapse of leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective study. Medicine (Baltimore) 98(19):e15584

    Article  Google Scholar 

  25. Okamoto Y, Kudo K, Tabuchi K, Tomizawa D et al (2019 Sep) Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. Bone Marrow Transplant 54(9):1489–1498

    Article  CAS  PubMed  Google Scholar 

  26. Walter RB, Buckley SA, John M. Pagel, et al. (2013) Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 122(10):1813–1821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Walter RB, Gooley TA, Wood BL, Milano F et al (2011) Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 29(9):1190–1197

    Article  PubMed  PubMed Central  Google Scholar 

  28. Raiola AM, Dominietto A, di Grazia C et al (2014) Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 20:1573e1579

    Article  Google Scholar 

  29. Miflin G, Russell NH, Franklin I, Cook G, Milligan DW et al (2000) An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. Cytotherapy. 2(6):423–428

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Si Pu Lan Road, Yanjiao Development Zone, Langfang, China

    Yue Lu, Yan-Li Zhao, Jian-Ping Zhang, Min Xiong, Xing-Yu Cao, De-Yan Liu, Rui-Juan Sun, Zhi-Jie Wei, Jia-Rui Zhou & Dao-Pei Lu

Authors
  1. Yue Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan-Li Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jian-Ping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Min Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xing-Yu Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. De-Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rui-Juan Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhi-Jie Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jia-Rui Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dao-Pei Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yue Lu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, Y., Zhao, YL., Zhang, JP. et al. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study. Ann Hematol 100, 1579–1591 (2021). https://doi.org/10.1007/s00277-020-04355-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04355-1

Keywords

Search

Navigation